New oral diabetes drugs may also protect patients' kidney health
Friday, August 19, 2016 - 08:31
in Health & Medicine
In a clinical trial of patients with type 2 diabetes, canagliflozin (a sodium-glucose cotransporter 2 inhibitor) slowed kidney function decline to a greater extent than glimepiride (a sulfonylurea), while having similar blood sugar–lowering effects, report investigators.